title: Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study.
abstract: Calcium fructoborate (CFB) has been reported as supporting healthy inflammatory response. In this study, we assess the effects of CFB on blood parameters and proinflammatory cytokines in healthy subjects. This was a randomized, double-blinded, placebo-controlled trial. Participants received placebo or CFB at a dose of 112 mg/day (CFB-1) or 56 mg/day (CFB-2) for 30 days. Glucose, total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), C-reactive protein (CRP), homocysteine, interleukin 1 beta (IL-1β), IL-6, and monocyte chemoattractant protein-1 (MCP-1) were determined before and after supplementation. CFB-1 showed a reduction in blood levels of CRP by 31.3 % compared to baseline. CFB-1 and CFB-2 reduced LDL levels by 9.8 and 9.4 %, respectively. CFB-1 decreased blood homocysteine by 5.5 % compared with baseline, whereas CFB-2 did not have a significant effect. Blood levels of TG were reduced by 9.1 and 8.8 % for CFB-1 and CFB-2, respectively. Use of both CFB-1 and CFB-2 resulted in significantly reduced IL-6 levels, when compared within and between groups. IL-1β was reduced by 29.2 % in the CFB-1 group. Finally, CFB-1 and CFB-2 reduced MCP-1 by 31 and 26 %, respectively. Our data indicate that 30-day supplementation with 112 mg/day CFB (CFB-1) resulted in a significant reduction of LDL, TG, TC, IL-1β, IL-6, MCP-1, and CRP. HDL levels were increased, when compared to baseline and placebo. These results suggest that CFB might provide beneficial support to healthy cardiovascular systems by positively affecting these blood markers (ClinicalTrials.gov, ISRCTN90543844; May 24, 2012 ( http://www.controlled-trials.com/ISRCTN90543844 )).
authors.affiliation: Department of Physical Medicine and Rehabilitation, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
authors.forename: Otilia-Constantina
authors.initials: OC
authors.lastname: Rogoveanu
authors.forename: George Dan
authors.initials: GD
authors.lastname: Mogoşanu
authors.forename: Cornelia
authors.initials: C
authors.lastname: Bejenaru
authors.forename: Ludovic Everard
authors.initials: LE
authors.lastname: Bejenaru
authors.forename: Octavian
authors.initials: O
authors.lastname: Croitoru
authors.forename: Johny
authors.initials: J
authors.lastname: Neamţu
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Pietrzkowski
authors.forename: Tania
authors.initials: T
authors.lastname: Reyes-Izquierdo
authors.forename: Andrei
authors.initials: A
authors.lastname: Biţă
authors.forename: Iulia Daria
authors.initials: ID
authors.lastname: Scorei
authors.forename: Romulus Ion
authors.initials: RI
authors.lastname: Scorei
mesh_terms: D000328:Adult; D001881:Borates / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000378:metabolism*; D018932:Chemokine CCL2 / Q000097:blood*; D002784:Cholesterol / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D001881:Borates; C111835:CCL2 protein, human; D018932:Chemokine CCL2; C508585:IL1B protein, human; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D008077:Lipoproteins, LDL; D014280:Triglycerides; C507177:calcium fructoborate; C032607:low density lipoprotein triglyceride; D005632:Fructose; D002097:C-Reactive Protein; D002784:Cholesterol